狭心症の世界市場レポート 2025年

狭心症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.1％で144億4,000万米ドルに成長します。予測期間の成長は、慢性心不全の有病率の増加、医薬品承認と臨床研究の増加、小売薬局の需要増加、心血管の健康に対する意識の高まり、医薬品需要の増加に起因しています。予測期間における主要動向としては、早期診断における技術進歩、血管形成術とステント留置術の進歩、新しい遺伝子治療アプローチ、冠動脈ステント需要、冠動脈疾患治療の進歩などが挙げられます。

冠動脈疾患患者の増加が予想され、狭心症市場の成長を牽引します。冠動脈疾患（CAD）は、冠動脈性心疾患（CHD）または虚血性心疾患（IHD）としても知られ、心筋への血液、酸素、栄養素の供給に重要な冠動脈の狭窄や閉塞を伴います。ライフスタイルの変化、環境因子、遺伝的素因がCADの有病率の上昇に寄与しています。狭心症は、CADの有病率を特定し評価するための極めて重要な指標であり、医療的評価、リスク層別化、治療決定、公衆衛生戦略の指針となります。例えば、米国心臓協会（American Heart Association）は、米国におけるCAD患者数が2021年の1,820万人から2023年1月には約1,930万人に増加すると報告しており、狭心症市場拡大の原動力となっています。

狭心症市場の大手企業は、CADと関連疾患の治療効果を高めるため、メトプロロール酒石酸塩錠のような革新的な医薬品の開発に注力しています。メトプロロール酒石酸塩錠は広く使用されている心血管系治療で、狭心症、高血圧、心不全など様々な疾患を対象としています。例えば、ザイダス社は2023年4月、25mg、50mg、100mgの強さのメトプロロール酒石酸塩錠USPのジェネリック医薬品を製造するFDAの承認を取得し、心血管疾患の治療選択肢を増やし、患者の転帰をサポートしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の狭心症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の狭心症市場：成長率分析
• 世界の狭心症市場の実績：規模と成長、2019～2024年
• 世界の狭心症市場の予測：規模と成長、2024～2029年、2034年
• 世界の狭心症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の狭心症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 狭心症ペクトリス
• 不安定狭心症
• プリンツメタル狭心症
• その他
• 世界の狭心症市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• ライフスタイルの変化
• 医薬品
• 血管形成術とステント留置術
• 冠動脈バイパス手術
• その他
• 世界の狭心症市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• ベータ遮断薬
• 硝酸塩とカルシウムチャネル遮断薬
• アンジオテンシン変換酵素阻害剤
• その他
• 世界の狭心症市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• クリニック
• 病院
• その他
• 世界の狭心症市場、狭心症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 安定した狭心症
• 慢性安定狭心症
• 努力誘発型狭心症
• 変異体または微小血管狭心症
• 世界の狭心症市場、不安定狭心症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性不安定狭心症
• 心筋梗塞前狭心症
• 残り狭心症
• 世界の狭心症市場、プリンツメタル狭心症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血管痙攣性狭心症
• 冠動脈痙攣誘発性狭心症
• バリアント狭心症
• 世界の狭心症市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 夜行性の狭心症
• 心筋梗塞後狭心症
• 狭心症無症候性心筋虚血症
• 狭心症大動脈弁狭窄症または弁疾患別

第7章 地域別・国別分析

• 世界の狭心症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の狭心症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 狭心症市場：競合情勢
• 狭心症市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Merck & Co Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott laboratories
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Troikaa Pharmaceuticals Ltd
• Amgen Inc.
• Dr. Reddy's Laboratories
• ViroMed Co. Ltd.
• Lee's Pharmaceutical Holdings

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 狭心症市場、2029年：新たな機会を提供する国
• 狭心症市場、2029年：新たな機会を提供するセグメント
• 狭心症市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Angina, also referred to as angina pectoris, presents as chest pain or discomfort caused by reduced blood flow to the heart muscle, typically due to blockages or narrowing of coronary arteries from atherosclerosis.

The primary types of angina include angina pectoris, unstable angina, Prinzmetal angina, and others. Angina pectoris, associated with coronary heart disease, results in chest pain or discomfort due to inadequate blood supply to the heart, often caused by arterial blockages. Treatment options range from lifestyle adjustments and medications to procedures such as angioplasty, stenting, and coronary bypass surgery. Commonly prescribed medications include beta-blockers, nitrates, calcium channel blockers, and angiotensin-converting enzyme inhibitors, utilized across various healthcare settings such as clinics and hospitals.

The angina market research report is one of a series of new reports from The Business Research Company that provides angina market statistics, including angina industry global market size, regional shares, competitors with an angina market share, detailed angina market segments, market trends, and opportunities, and any further data you may need to thrive in the angina industry. This angina market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The angina market size has grown strongly in recent years. It will grow from $10.71 billion in 2024 to $11.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased prevalence of coronary heart disease, increased use of vasodilators, increased prevalence of myocardial ischemia, improved diagnostic capabilities, increased use of imaging techniques.

The angina market size is expected to see strong growth in the next few years. It will grow to $14.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing prevalence of chronic angina pectoris, rising drug approvals and clinical research, increasing demand for retail pharmacies, growing awareness of cardiovascular health, growing demand for medications. Major trends in the forecast period include technological advancements in early diagnosis, advancements in angioplasty and stenting, new gene therapy approaches, demand for coronary stents, advancements in coronary artery disease treatment.

The anticipated increase in coronary artery disease cases is set to drive growth in the angina market. Coronary artery disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease (IHD), involves the narrowing or blockage of coronary arteries, critical for supplying blood, oxygen, and nutrients to the heart muscle. Lifestyle changes, environmental factors, and genetic predispositions contribute to the rising prevalence of CAD. Angina serves as a pivotal indicator for identifying and assessing CAD prevalence, guiding medical evaluations, risk stratification, treatment decisions, and public health strategies. For instance, the American Heart Association reported a rise in adults living with CAD in the U.S. from 18.2 million in 2021 to approximately 19.3 million in January 2023, underscoring the driving force behind the angina market's expansion.

Leading firms in the angina market are focusing on developing innovative medications such as metoprolol tartrate tablets to enhance treatment efficacy for CAD and related conditions. Metoprolol tartrate tablets, a widely used cardiovascular medication, target various conditions such as angina, hypertension, and heart failure. For example, Zydus received FDA approval in April 2023 to produce generic versions of Metoprolol Tartrate Tablets USP in strengths of 25 mg, 50 mg, and 100 mg, bolstering treatment options for cardiovascular ailments and supporting patient outcomes.

In March 2024, Novo Nordisk acquired Cardior Pharmaceuticals for $1.10 billion (€1.025 billion), aiming to fortify its cardiovascular therapeutic pipeline. This acquisition integrates Cardior's RNA-based therapeutics, notably CDR132L, currently in Phase II clinical trials for heart failure treatment, thereby expanding Novo Nordisk's capabilities in managing cardiovascular diseases. Cardior Pharmaceuticals, headquartered in Germany, specializes in angiotensin-converting enzyme inhibitors, contributing further to Novo Nordisk's strategic expansion in cardiovascular care.

Major companies operating in the angina market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Troikaa Pharmaceuticals Ltd, Amgen Inc., Dr. Reddy's Laboratories, ViroMed Co. Ltd., Lee's Pharmaceutical Holdings, Kuhnil Pharmaceutical, LegoChem Biosciences, Axus Cardium Pharmaceuticals, Juventas Therapeutics, Milestone Pharmaceuticals

North America was the largest region in the angina market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the angina market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The angina market consists of revenues earned by entities by providing treatments for stable angina, and microvascular angina. The market value includes the value of related goods sold by the service provider or included within the service offering. The angina market also includes sales of anticoagulants and statins. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Angina Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angina market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angina ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The angina market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Angina Pectoris; Unstable Angina; Prinzmetal Angina; Other Types
• 2) By Treatment: Lifestyle Changes; Medications; Angioplasty And Stenting; Coronary Bypass Surgery; Other Treatments
• 3) By Drug Class: Beta Blockers; Nitrates And Calcium Channel Blockers; Angiotensin-Converting Enzyme Inhibitors; Other Drug Classes
• 4) By Application: Clinics; Hospitals; Other Applications
• Subsegments:
• 1) By Angina Pectoris: Stable Angina; Chronic Stable Angina; Effort-Induced Angina; Variant Or Microvascular Angina
• 2) By Unstable Angina: Acute Unstable Angina; Pre-Infarction Angina; Rest Angina
• 3) By Prinzmetal Angina: Vasospastic Angina; Coronary Artery Spasm-Induced Angina; Variant Angina
• 4) By Other Types: Nocturnal Angina; Post-Infarction Angina; Angina With Silent Myocardial Ischemia; Angina Due To Aortic Stenosis Or Valve Disease
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Angina Market Characteristics

3. Angina Market Trends And Strategies

4. Angina Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Angina Growth Analysis And Strategic Analysis Framework

• 5.1. Global Angina PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Angina Market Growth Rate Analysis
• 5.4. Global Angina Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Angina Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Angina Total Addressable Market (TAM)

6. Angina Market Segmentation

• 6.1. Global Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angina Pectoris
• Unstable Angina
• Prinzmetal Angina
• Other Types
• 6.2. Global Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lifestyle Changes
• Medications
• Angioplasty And Stenting
• Coronary Bypass Surgery
• Other Treatments
• 6.3. Global Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Blockers
• Nitrates And Calcium Channel Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Other Drug Classes
• 6.4. Global Angina Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other Applications
• 6.5. Global Angina Market, Sub-Segmentation Of Angina Pectoris, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stable Angina
• Chronic Stable Angina
• Effort-Induced Angina
• Variant Or Microvascular Angina
• 6.6. Global Angina Market, Sub-Segmentation Of Unstable Angina, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Unstable Angina
• Pre-Infarction Angina
• Rest Angina
• 6.7. Global Angina Market, Sub-Segmentation Of Prinzmetal Angina, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vasospastic Angina
• Coronary Artery Spasm-Induced Angina
• Variant Angina
• 6.8. Global Angina Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nocturnal Angina
• Post-Infarction Angina
• Angina With Silent Myocardial Ischemia
• Angina Due To Aortic Stenosis Or Valve Disease

7. Angina Market Regional And Country Analysis

• 7.1. Global Angina Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Angina Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Angina Market

• 8.1. Asia-Pacific Angina Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Angina Market

• 9.1. China Angina Market Overview
• 9.2. China Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Angina Market

• 10.1. India Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Angina Market

• 11.1. Japan Angina Market Overview
• 11.2. Japan Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Angina Market

• 12.1. Australia Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Angina Market

• 13.1. Indonesia Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Angina Market

• 14.1. South Korea Angina Market Overview
• 14.2. South Korea Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Angina Market

• 15.1. Western Europe Angina Market Overview
• 15.2. Western Europe Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Angina Market

• 16.1. UK Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Angina Market

• 17.1. Germany Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Angina Market

• 18.1. France Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Angina Market

• 19.1. Italy Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Angina Market

• 20.1. Spain Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Angina Market

• 21.1. Eastern Europe Angina Market Overview
• 21.2. Eastern Europe Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Angina Market

• 22.1. Russia Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Angina Market

• 23.1. North America Angina Market Overview
• 23.2. North America Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Angina Market

• 24.1. USA Angina Market Overview
• 24.2. USA Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Angina Market

• 25.1. Canada Angina Market Overview
• 25.2. Canada Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Angina Market

• 26.1. South America Angina Market Overview
• 26.2. South America Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Angina Market

• 27.1. Brazil Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Angina Market

• 28.1. Middle East Angina Market Overview
• 28.2. Middle East Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Angina Market

• 29.1. Africa Angina Market Overview
• 29.2. Africa Angina Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Angina Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Angina Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Angina Market Competitive Landscape And Company Profiles

• 30.1. Angina Market Competitive Landscape
• 30.2. Angina Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Angina Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Novartis AG
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Abbott laboratories
• 31.6. GlaxoSmithKline Plc
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Troikaa Pharmaceuticals Ltd
• 31.12. Amgen Inc.
• 31.13. Dr. Reddy's Laboratories
• 31.14. ViroMed Co. Ltd.
• 31.15. Lee's Pharmaceutical Holdings

32. Global Angina Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Angina Market

34. Recent Developments In The Angina Market

35. Angina Market High Potential Countries, Segments and Strategies

• 35.1 Angina Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Angina Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Angina Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer